Atulkumar Roy, MD
Nephrology · Merced, CANPI 1467496505
Payments from drug & device makers
Across 63 payments — averaging $24.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$336
- AstraZeneca$278
- Mallinckrodt Hospital Products Inc.$137
- GSK$137
- Fresenius USA Marketing, Inc.$89
- Medtronic$89
- plus $474 from 11 others
What the payments were for
- Food & beverage$1,35488%
- Education$18412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $336 |
| AstraZeneca(2 entities) | 10 | $278 |
| Mallinckrodt Hospital Products Inc. | 3 | $137 |
| GSK | 3 | $137 |
| Fresenius USA Marketing, Inc. | 6 | $89 |
| Medtronic | 2 | $89 |
| Akebia Therapeutics Inc | 5 | $86 |
| Bayer | 5 | $85 |
| Boehringer Ingelheim | 3 | $72 |
| OPKO Pharmaceuticals, LLC | 2 | $44 |
| Vantive US Healthcare LLC | 1 | $39 |
| Ultragenyx Pharmaceutical Inc. | 1 | $36 |
| Vifor Pharma, Inc. | 2 | $31 |
| Novartis | 2 | $30 |
| Amgen | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Aurinia Pharma U.S., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,538 in reported general payments places this provider in the 50th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 200 | $602,106 |
| JardianceEmpagliflozin | 185 | $256,791 |
| FarxigaDapagliflozin Propanediol | 180 | $207,052 |
| TrulicityDulaglutide | 44 | $77,374 |
| KerendiaFinerenone | 51 | $72,557 |
| OzempicSemaglutide | 48 | $59,414 |
| VelphoroSucroferric Oxyhydroxide | 12 | $44,778 |
| LokelmaSodium Zirconium Cyclosilicate | 28 | $38,236 |
| Sevelamer Carbonate | 85 | $31,144 |
| Cinacalcet Hcl | 46 | $21,828 |
| ProsolParenteral Amino Acid 20% No.1 | 123 | $18,820 |
| RayaldeeCalcifediol | 13 | $17,279 |
| JanuviaSitagliptin Phosphate | 13 | $12,985 |
| Calcium Acetate | 72 | $11,669 |
| Tacrolimus | 19 | $2,231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $72 | $256,791185 claims |
| AstraZenecaFarxiga, Lokelma | $278 | $245,289208 claims |
| BayerKerendia | $85 | $72,55751 claims |
| Novo NordiskOzempic | $336 | $59,41448 claims |
| Fresenius USA Marketing, Inc.Velphoro | $89 | $44,77812 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $44 | $17,27913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,341 nephrology providers in California.
Other nephrology in Merced
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.